Protagenic Therapeutics enjoys a productive relationship with the University of Toronto, including a worldwide exclusive license to commercialize the peptide upon which PT00014 is based. The relationship between the Company and the University is mutually-beneficial; born of the profound necessity to realize the potential of a promising molecular drug candidate, and fostered by the practical, realistic, and ultimately effective stance that the University of Toronto has taken regarding this molecule. The University’s graduate student and post-doc population is imbued with an entrepreneurial pro-translational attitude. They take pride in seeing steps taken by the company toward the eventually use of their work to benefit patients. Likewise, the company takes pride in being able to create value for all its stakeholders by this translation of basic science to practical application to an eventual commercially-available pharmaceutical that makes a big difference in the lives of patients.
As of September 21, 2016, the University of Toronto was ranked the single best research university in Canada, and the 22nd best university in the world by the Times Higher Education (THE) World University Rankings for 2016-2017. The THE rankings cited the breadth of the University of Toronto’s research programs as a distinguishing factor.